Forest Laboratories Inc (FRX)

99.00
0.77 0.77
Prev Close 99.77
Open 100.03
Day Low/High 99.00 / 100.46
52 Wk Low/High 40.63 / 100.88
Volume 11.10M
Avg Volume 2.54M
Exchange
Shares Outstanding 272.59M
Market Cap 26.99B
EPS 0.61
Div & Yield N.A. (N.A)

Latest News

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Teva, Actavis, Other Generic Drugmakers May Be on Acquisition Trail

Mylan's deal to buy Perrigo is taking another potential target off the block.

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

Jim Cramer -- Deal Activity in Specialty Pharma Reaches a Frenzied Pace

The recent bid by Mylan to acquire Perrigo offers the latest example of pharma companies that have been seeking growth opportunities.

Why Endo International Can Deliver Solid Rewards With Minimal Risk

Why Endo International Can Deliver Solid Rewards With Minimal Risk

With the recent deal for DAVA, Endo is now one of the best health care stocks to own.

Actavis And Forest Receive U.S. FTC Clearance For Actavis’ Proposed Acquisition Of Forest

Actavis And Forest Receive U.S. FTC Clearance For Actavis’ Proposed Acquisition Of Forest

Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the U.

Actavis And Forest Announce Preliminary Stockholder Merger Consideration Election Results

Actavis And Forest Announce Preliminary Stockholder Merger Consideration Election Results

Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced the preliminary results of the elections made by stockholders of Forest regarding their preference as to the form of merger consideration...

Actavis And Forest Announce Tentative Election Deadline Of June 27, 2014

Actavis And Forest Announce Tentative Election Deadline Of June 27, 2014

Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that the tentative election deadline for Forest stockholders to elect the form of consideration they wish to receive in Actavis’ ...

Forest Laboratories, Inc. Announces Positive Topline Results From Three Phase III Trials For Vilazodone In The Treatment Of Generalized Anxiety Disorder (GAD)

Forest Laboratories, Inc. Announces Positive Topline Results From Three Phase III Trials For Vilazodone In The Treatment Of Generalized Anxiety Disorder (GAD)

Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety ...

3 Stocks Driving The Health Care Sector Higher

3 Stocks Driving The Health Care Sector Higher

TheStreet highlights 3 stocks pushing the health care sector higher today.

Trade-Ideas: Forest Laboratories (FRX) Is Today's Momo Momentum Stock

Trade-Ideas: Forest Laboratories (FRX) Is Today's Momo Momentum Stock

Trade-Ideas LLC identified Forest Laboratories (FRX) as a momo momentum candidate

Actavis And Forest Laboratories Announce Appointment Of C. David Nicholson, PhD To Lead Actavis Global Brands Research And Development

Actavis And Forest Laboratories Announce Appointment Of C. David Nicholson, PhD To Lead Actavis Global Brands Research And Development

- Will join Actavis as Senior Vice President, Global Brands R&D Following close of the acquisition of Forest -

Actavis And Forest Laboratories Announce Appointment Of C. David Nicholson, PhD To Lead Actavis Global Brands Research And Development

Actavis And Forest Laboratories Announce Appointment Of C. David Nicholson, PhD To Lead Actavis Global Brands Research And Development

Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that C.

Forest Laboratories, Inc. To Present Cariprazine Data At The International College Of Neuropsychopharmacology World Congress

Forest Laboratories, Inc. To Present Cariprazine Data At The International College Of Neuropsychopharmacology World Congress

Forest Laboratories, Inc. (NYSE:FRX) today announced that data on the investigational drug cariprazine will be presented at the International College of Neuropsychopharmacology (CINP) 29th World Congress, scheduled ...

Forest Obtains Six Months U.S. Pediatric Exclusivity For NAMENDA® And NAMENDA XR®

Forest Obtains Six Months U.S. Pediatric Exclusivity For NAMENDA® And NAMENDA XR®

Forest Laboratories, Inc. (NYSE:FRX) announced today that the U.

Actavis And Forest Shareholders Approve Proposals Related To Actavis’ Planned Acquisition Of Forest

Actavis And Forest Shareholders Approve Proposals Related To Actavis’ Planned Acquisition Of Forest

Actavis plc (NYSE:ACT) and Forest Laboratories, Inc. (NYSE:FRX) today announced that, at shareholder meetings held today, all proposals related to Actavis’ planned acquisition of Forest were approved by both ...

COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier To Effective Management

COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier To Effective Management

Patients with chronic obstructive pulmonary disease (COPD) may need more education and better dialogue with their physicians to effectively manage the progressive respiratory condition and potentially life-threatening...

Forest Laboratories, Inc. Announces Receipt Of Requisite Consents And Expiration Of Consent Solicitations For Certain Of Its Senior Notes

Forest Laboratories, Inc. Announces Receipt Of Requisite Consents And Expiration Of Consent Solicitations For Certain Of Its Senior Notes

Forest Laboratories, Inc. (NYSE:FRX) today announced that it had received valid consents (the “Requisite Consents”) from holders of a majority in aggregate principal amount of each series of its securities ...

Forest Laboratories Announces Intention To Continue Marketing Both NAMENDA® TABLETS And Once-Daily NAMENDA XR® Into The Fall Of 2014

Forest Laboratories Announces Intention To Continue Marketing Both NAMENDA® TABLETS And Once-Daily NAMENDA XR® Into The Fall Of 2014

Forest Laboratories, Inc. (NYSE:FRX), a leading, fully integrated, specialty pharmaceutical company, today announced that it intends to continue to market both its NAMENDA ® (memantine HCl) 5 mg and 10 mg tablets...

Forest Laboratories, Inc. Extends Expiration Time Of Consent Solicitations To Eliminate Existing Registration Rights Obligations On Certain Of Its Senior Notes

Forest Laboratories, Inc. Extends Expiration Time Of Consent Solicitations To Eliminate Existing Registration Rights Obligations On Certain Of Its Senior Notes

Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the “Consent Solicitations”) to eliminate existing registration rights obligations ...

Forest Laboratories, Inc. Announces Publication In The Lancet Of Pivotal Phase III Hypertension Trial Of The Fixed-Dose Combination Of Nebivolol/Valsartan

Forest Laboratories, Inc. Announces Publication In The Lancet Of Pivotal Phase III Hypertension Trial Of The Fixed-Dose Combination Of Nebivolol/Valsartan

Forest Laboratories, Inc. (NYSE:FRX) today announced the publication of data from its pivotal Phase III Study of an Investigational Fixed-Dose Combination (FDC) of nebivolol and valsartan in the May 30, 2014 issue of...

FRX, AZN And ACT, 3 Health Care Stocks Pushing The Sector Lower

FRX, AZN And ACT, 3 Health Care Stocks Pushing The Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Forest Laboratories, Inc. Commences Consent Solicitations To Eliminate Existing Registration Rights Obligations On Certain Of Its Senior Notes

Forest Laboratories, Inc. Commences Consent Solicitations To Eliminate Existing Registration Rights Obligations On Certain Of Its Senior Notes

Forest Laboratories, Inc. (NYSE: FRX) today announced that, subject to the close of the pending acquisition (the “Acquisition”) of Forest by Actavis plc (NYSE: ACT), Actavis is offering to guarantee certain of ...

Will This Price Target Increase Help Forest Laboratory (FRX) Stock Today?

Will This Price Target Increase Help Forest Laboratory (FRX) Stock Today?

UBS raises its price target for Forest Laboratory (FRX) to $94 from $72, reiterating its 'neutral' rating, citing a recent takeover offer.

Forest Laboratories, Inc. To Present Nebivolol/Valsartan Fixed-Dose Combination Data At The American Society Of Hypertension Annual Scientific Meeting

Forest Laboratories, Inc. To Present Nebivolol/Valsartan Fixed-Dose Combination Data At The American Society Of Hypertension Annual Scientific Meeting

Forest Laboratories, Inc. (NYSE:FRX) today announced that data on an investigational fixed-dose combination (FDC) of nebivolol and valsartan will be presented at the American Society of Hypertension (ASH) Annual ...

Forest Laboratories, Inc. To Present Data About Aclidinium, Aclidinium/Formoterol Combination, And Roflumilast At The American Thoracic Society International Conference

Forest Laboratories, Inc. To Present Data About Aclidinium, Aclidinium/Formoterol Combination, And Roflumilast At The American Thoracic Society International Conference

Forest Laboratories, Inc. (NYSE:FRX) today announced that it will present data on aclidinium, aclidinium/formoterol combination, and roflumilast at the American Thoracic Society (ATS) 2014 International Conference...

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet highlights 3 stocks pushing the health care sector lower today.

Forest Laboratories Inc (FRX): Today's Featured Drugs Laggard

Forest Laboratories Inc (FRX): Today's Featured Drugs Laggard

Forest Laboratories was a leading decliner within the drugs industry, falling $1.71 (-1.8%) to $91.78 on light volume